Microparticles Carrying Sonic Hedgehog Favor Neovascularization Through the Activation of Nitric Oxide Pathway in Mice
Overview
Authors
Affiliations
Background: Microparticles (MPs) are vesicles released from plasma membrane upon cell activation and during apoptosis. Human T lymphocytes undergoing activation and apoptosis generate MPs bearing morphogen Shh (MPs(Shh+)) that are able to regulate in vitro angiogenesis.
Methodology/principal Findings: Here, we investigated the ability of MPs(Shh+) to modulate neovascularization in a model of mouse hind limb ischemia. Mice were treated in vivo for 21 days with vehicle, MPs(Shh+), MPs(Shh+) plus cyclopamine or cyclopamine alone, an inhibitor of Shh signalling. Laser doppler analysis revealed that the recovery of the blood flow was 1.4 fold higher in MPs(Shh+)-treated mice than in controls, and this was associated with an activation of Shh pathway in muscles and an increase in NO production in both aorta and muscles. MPs(Shh+)-mediated effects on flow recovery and NO production were completely prevented when Shh signalling was inhibited by cyclopamine. In aorta, MPs(Shh+) increased activation of eNOS/Akt pathway, and VEGF expression, being inhibited by cyclopamine. By contrast, in muscles, MPs(Shh+) enhanced eNOS expression and phosphorylation and decreased caveolin-1 expression, but cyclopamine prevented only the effects of MPs(Shh+) on eNOS pathway. Quantitative RT-PCR revealed that MPs(Shh+) treatment increased FGF5, FGF2, VEGF A and C mRNA levels and decreased those of α5-integrin, FLT-4, HGF, IGF-1, KDR, MCP-1, MT1-MMP, MMP-2, TGFβ1, TGFβ2, TSP-1 and VCAM-1, in ischemic muscles.
Conclusions/significance: These findings suggest that MPs(Shh+) may contribute to reparative neovascularization after ischemic injury by regulating NO pathway and genes involved in angiogenesis.
Chideriotis S, Anastasiadi A, Tzounakas V, Fortis S, Kriebardis A, Valsami S Int J Mol Sci. 2025; 26(3).
PMID: 39940651 PMC: 11816454. DOI: 10.3390/ijms26030881.
Therapeutic implication of Sonic Hedgehog as a potential modulator in ischemic injury.
Mohan M, Mannan A, Singh T Pharmacol Rep. 2023; 75(4):838-860.
PMID: 37347388 DOI: 10.1007/s43440-023-00505-0.
Blood Cell-Derived Microvesicles in Hematological Diseases and beyond.
Georgatzakou H, Fortis S, Papageorgiou E, Antonelou M, Kriebardis A Biomolecules. 2022; 12(6).
PMID: 35740926 PMC: 9220817. DOI: 10.3390/biom12060803.
Extracellular Vesicles as Drivers of Immunoinflammation in Atherothrombosis.
Suades R, Greco M, Padro T, Badimon L Cells. 2022; 11(11).
PMID: 35681540 PMC: 9180657. DOI: 10.3390/cells11111845.
Martin-Ventura J, Roncal C, Orbe J, Blanco-Colio L Front Cell Dev Biol. 2022; 10:813885.
PMID: 35155428 PMC: 8827403. DOI: 10.3389/fcell.2022.813885.